This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Nektar Gears Up to Report Q2 Earnings: What's in the Cards?
by Zacks Equity Research
NKTR is due to report second-quarter results. Investors await fresh updates on rezpeg's progress across autoimmune trials.
Journey Medical Corporation (DERM) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
Journey Medical (DERM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
NKTR Stock Soars as Lead Drug Meets Goal in Atopic Dermatitis Study
by Zacks Equity Research
Nektar's lead candidate, rezpeg, hits key targets in a phase IIb eczema study, sending shares soaring 156.3% on Tuesday.
Strength Seen in Nektar (NKTR): Can Its 12.1% Jump Turn into More Strength?
by Zacks Equity Research
Nektar (NKTR) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Nektar Q1 Loss Wider Than Expected, Revenues Fall Y/Y, Stock Down
by Zacks Equity Research
NKTR incurs a wider-than-expected loss in the first quarter of 2025. Revenues plunge year over year. Shares fall in after-hours trading.
Nektar Therapeutics (NKTR) Reports Q1 Loss, Lags Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of -22.22% and 40.47%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
Will Nektar Therapeutics (NKTR) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Nektar (NKTR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Nektar (NKTR) Down 38.8% Since Last Earnings Report?
by Zacks Equity Research
Nektar (NKTR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nektar Therapeutics (NKTR) Q4 Earnings Miss Estimates (Revised)
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of -15.38% and 25.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Nektar Q4 Loss Wider Than Expected, Pipeline in Focus, Stock Up
by Zacks Equity Research
NKTR fourth-quarter earnings and revenues lag estimates. 2025 is poised to be a catalyst year for rezpeg, with multiple data readouts expected. Stock rises.
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
The headline numbers for Nektar (NKTR) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Nektar (NKTR) Reports Q4 Earnings: What Key Metrics Have to Say
by Zacks Equity Research
While the top- and bottom-line numbers for Nektar (NKTR) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Nektar Therapeutics (NKTR) Q4 Earnings Beat Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 215.38% and 25.23%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Assertio (ASRT) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Assertio (ASRT) delivered earnings and revenue surprises of -175% and 7.54%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -47.22% and 84.18%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Zoetis (ZTS) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Zoetis (ZTS) delivered earnings and revenue surprises of 2.19% and 0.68%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Down -38.51% in 4 Weeks, Here's Why Nektar (NKTR) Looks Ripe for a Turnaround
by Zacks Equity Research
Nektar (NKTR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Zacks Industry Outlook Highlights Corcept, Amneal, Dyne, Nektar and Cardiol
by Zacks Equity Research
Corcept, Amneal, Dyne, Nektar and Cardiol have been highlighted in this Industry Outlook article.
Nektar (NKTR) Could Find a Support Soon, Here's Why You Should Buy the Stock Now
by Zacks Equity Research
Nektar (NKTR) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
5 Small Drug Stocks to Add to Your Kitty in the Trump 2.0 Era
by Kinjel Shah
Innovation is at its peak for the Zacks Medical-Drugs industry. CORT, AMRX, DYN, NKTR and CRDL may prove to be good additions to one's portfolio.
MediWound (MDWD) Surges 8.5%: Is This an Indication of Further Gains?
by Zacks Equity Research
MediWound (MDWD) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Nektar Q3 Loss Narrower Than Expected, Pipeline Development in Focus
by Zacks Equity Research
NKTR reports encouraging third-quarter results as both earnings and revenues beat estimates. Product sales increase year over year.
Nektar Therapeutics (NKTR) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Nektar (NKTR) delivered earnings and revenue surprises of 21.74% and 55.24%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Why Is Esperion Therapeutics (ESPR) Down 3.9% Since Last Earnings Report?
by Zacks Equity Research
Esperion Therapeutics (ESPR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
What Makes Nektar (NKTR) a New Buy Stock
by Zacks Equity Research
Nektar (NKTR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.